Diflunisal Offlabel denied as non-formulary by Humana?
Non-formulary doesn't mean uncoverable. Most plans have a formulary-exception process: the appeal needs to show the formulary alternatives are inappropriate for your specific clinical situation.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Humana typically requires
Humana's specific coverage criteria for diflunisal offlabel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Humana angle on Diflunisal Offlabel
## Why Humana Denied Diflunisal (Off-Label Use) as Non-Formulary
Diflunisal is a generic NSAID that may appear on Humana's formulary at a standard tier for its on-label analgesic indication. However, when prescribed off-label for transthyretin amyloidosis, Humana may deny coverage because: (1) the off-label indication triggers a separate coverage policy that excludes or limits the drug for that use, even if the drug itself is on-formulary; or (2) the drug's formulary position requires prior authorization for certain uses and that PA was not obtained. Check whether the denial is truly a formulary classification issue or whether it is a coverage-policy denial for the off-label indication — the appeal path differs.
## Why This Denial Is Appealable
If the drug is on-formulary for any indication, a non-formulary denial for an off-label use may be contestable on the grounds that the plan's formulary exclusion for off-label use is inconsistent with the plan's own coverage terms or with applicable state law on off-label drug coverage. Many states require coverage of off-label drug use when supported by recognized compendia or peer-reviewed literature. Check whether your state has such a law and whether it applies to your plan type (fully-insured plans are subject to state law; self-funded ERISA plans generally are not, though ERISA still requires full-and-fair review).
## Federal Appeal Framework
Under ACA Section 2719 and ERISA Section 503, non-formulary denials are adverse benefit determinations subject to mandatory internal appeal and independent external review. File the internal appeal within the deadline on the denial notice (typically 180 days). After a final internal denial, request external review within four months. For medically urgent situations, expedited external review must be decided within 72 hours.
## Documentation to Gather
- Formulary documentation: A copy of Humana's formulary (the version in effect at the time of the prescription) and the relevant coverage-policy document addressing off-label use — both available from Humana's website or by calling the member services line.
- State law research: Determine whether your state's off-label drug coverage law applies to the plan type and, if so, include the citation in the appeal letter.
- Diagnosis and medical necessity: Records confirming the ATTR amyloidosis diagnosis and the prescribing rationale, including specialist notes.
- Prescriber letter: A letter from the prescribing physician explaining the off-label use, its evidence basis (referencing the applicable professional society guidance generically), and the clinical necessity for this specific patient.
- Literature support: The prescriber or a specialist should note the peer-reviewed evidence base supporting this use — without citing specific trial statistics — so that Humana's reviewer and any external reviewer can assess whether the compendia standard is met.
## Criteria-Mapping Structure
| Humana Non-Formulary / Off-Label Coverage Requirement | Patient-Specific Supporting Evidence | |---|---| | [Each criterion from Humana's formulary exception or off-label policy, verbatim] | [Chart evidence, specialist note, or literature reference addressing that criterion] |
If Humana's formulary exception process has a separate form or submission portal, use it in parallel with the standard appeal — some plans have faster resolution through the formulary exception track.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →